AKC Canine Health Foundation Receives $96k from Purina Parent Club Partnership Program for Canine Health Research
RALEIGH, N.C., May 15, 2025 /PRNewswire/ -- The AKC Canine Health Foundation (CHF), a nonprofit organization dedicated to improving the lives of all dogs through knowledge and discovery, announces a substantial research investment through its ongoing collaboration with Purina® and dedicated breed organizations. Through the Purina Parent Club Partnership (PPCP) Program, $95,573 has been directed toward innovative canine health research that directly benefits dogs.
This donation continues a longstanding collaboration between CHF and Purina that has channeled more than $9 million into canine health research, breed rescue, and educational efforts since 2002. CHF is grateful for Purina's commitment to using the PPCP program to fund programs that advance the future of canine health.
PPCP creates a direct line between passionate breed enthusiasts and the scientific advances that help their dogs live longer lives, allowing Purina® Pro Club® members to put the Purina Points they've earned, by purchasing qualifying pet foods and submitting proofs of purchase, towards canine health research. An annual donation from Purina is shared between Purina Pro Club members' designated parent breed club and that breed club's Donor Advised Fund at CHF.
"We are proud to continue supporting canine health research through the PPCP Program," says Scott Smith, Managing Director at Purina and CHF Board Member. "The program's success is a testament to our shared goal: to give dogs healthier lives."
"We are grateful for the generous support Purina provides year after year through this program," said Dr. Stephanie Montgomery, Chief Executive Officer, AKC Canine Health Foundation. "Thanks to their sustained commitment, dedicated dog lovers and breed clubs play an influential role in advancing research that improves the health of the dogs we cherish."
Additional collaborations between these two organizations include Purina's sponsorship of CHF's biennial National Parent Club Canine Health Conference and the commemorative brick program at the Event Center at Purina Farms in Gray Summit, MO (akcchf.org/brick). These programs embody the shared commitment between Purina, CHF, and breed organizations to support healthy vibrant lives for the dogs that enrich our world.
About CHF
Since 1995, the AKC Canine Health Foundation has leveraged the power of science to address the health needs of all dogs. With more than $75 million in funding to date, the Foundation provides grants for the highest quality canine health research and shares information on the discoveries that help prevent, treat and cure canine diseases. The Foundation meets and exceeds industry standards for fiscal responsibility, as demonstrated by their highest four-star Charity Navigator rating and Candid Platinum Seal of Transparency. Learn more at www.akcchf.org.
About Purina
Nestlé Purina PetCare creates richer lives for pets and the people who love them. Founded in 1894, Purina has helped dogs and cats live longer, healthier lives by offering scientifically based nutritional innovations.
Purina manufactures some of the world's most trusted and popular pet care products, including Pro Plan, Purina ONE, Friskies and Tidy Cats. Our more than 11,000 U.S. associates take pride in our trusted pet food, treat and litter brands that feed 46 million dogs and 68 million cats every year. Nearly 500 Purina scientists, veterinarians, and pet care experts ensure our commitment to unsurpassed quality and nutrition.
Purina Pro Plan is a leader in the advanced nutrition category, with more than 140 targeted formulas to help your pet thrive throughout every stage of life. For more information, visit www.proplan.com or follow @ProPlan on Twitter, Instagram, or Facebook.
Over the past five years, Purina has contributed more than $150 million towards organizations that bring, and keep, people and pets together, as well as those that help our communities and environment thrive.
Purina is part of Nestlé, a global leader in Nutrition, Health and Wellness. For more information, visit purina.com or subscribe here to get the latest Purina news.
View original content:https://www.prnewswire.com/news-releases/akc-canine-health-foundation-receives-96k-from-purina-parent-club-partnership-program-for-canine-health-research-302456933.html
SOURCE AKC Canine Health Foundation
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
SciBase Initiates Self-Pay Model in the US to Make Nevisense Test More Accessible to Patients
STOCKHOLM, June 9, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders, today announced the launch of the Nevisense Self-Pay Program in the US, a new initiative designed to improve patient access to the Nevisense test outside of traditional insurance coverage. The program is being implemented at dermatology practices enrolled in the self-pay solution and addresses increasing demand for the Nevisense test directly from patients and dermatologists. SciBase has enrolled several practices located throughout the US and plans to further expand the program to meet clinician and patient needs. Driven by evolving standards of care and a growing clinical emphasis on early detection, dermatologists have shown a strong interest in making Nevisense available to patients irrespective of payer status. The new Self-Pay Program empowers clinicians to incorporate Nevisense into their diagnostic workflow sooner - ensuring that patients at risk for melanoma are not left waiting due to insurance limitations. "We continue to work diligently to expand payer coverage and reimbursement, but we also recognize the urgent need for early detection," said Pia Renaudin, CEO of SciBase. "The Self-Pay Program is a critical step in making Nevisense more widely available to clinicians and patients who value early, accurate melanoma detection at the point of care." As melanoma rates continue to rise globally, the importance of early diagnosis has never been greater. Nevisense offers a point-of-care solution that enhances clinical decision-making and supports earlier detection - ultimately improving outcomes and reducing the long-term burden on healthcare systems. With the introduction of the Self-Pay Program, SciBase is reinforcing its commitment to innovation, access, and sustainable healthcare. The initiative enables more patients to benefit from Nevisense while helping clinicians deliver exceptional care through early melanoma detection. For additional information, please contact:Pia Renaudin, CEO, tel. +46732069802, e-mail: Certified Advisor (CA): DNB Carnegie Investment Bank AB (publ) Phone: +46 (0)73 856 42 65 E-mail: certifiedadviser@ About SciBase SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops, manufactures, and commercializes Nevisense, a unique point-of-care platform that combines AI and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management. Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs. Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements. The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is Carnegie Investment Bank AB (publ). Learn more at For press releases and financial reports visit: This information was brought to you by Cision The following files are available for download: US cashpay v1 View original content: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Yahoo
Idorsia publishes invitations to bondholder meetings
Ad hoc announcement pursuant to Art. 53 LR Bondholder meetings will take place on Wednesday, June 25, 2025, to vote on proposals to amend the terms of the two outstanding convertible bonds CB 2025 and CB 2028 Allschwil, Switzerland – June 6, 2025Idorsia Ltd (SIX: IDIA) today announced that following the expiry of the appeal period for the amended terms approved at the CB 2025 bondholder meeting of February 25, 2025 – during which no appeal was filed – it has published invitations to the next bondholder meetings for holders of its outstanding CHF 200 million convertible bonds maturing in 2025 (CB 2025; ISIN CH0426820350), and CHF 600 million convertible bonds maturing in 2028 (CB 2028; ISIN CH1128004079). At the meetings, the company will propose changing the current terms of the CB 2025 and CB 2028 as part of the larger holistic restructuring, as announced in a press release on February 26, 2025, and an update published on May 21, 2025. To date, approximately 87% of the holders of the CB 2025 and 90% of holders of the CB 2028 have entered a legally binding lockup agreement in support of the holistic restructuring. Such bondholders have committed to vote in favour of the proposed amendments to the terms of the CB 2025 and CB 2028 at or before the meeting. The amendment of the terms of the CB 2025 and CB 2028 will be conditional on the consummation of the exchange offer, which is expected to be launched around or following the date of the bondholder meetings. Bondholders can access the invitations to the two bondholder meetings scheduled for Wednesday, June 25, 2025, including the terms of the resolution and additional information about the meeting, as well as a financial status report as of April 30, 2025, at the following links: and Notes to the editor About IdorsiaIdorsia Ltd is reaching out for more – we have more passion for science, we see more opportunities, and we want to help more patients. The purpose of Idorsia is to challenge accepted medical paradigms, answering the questions that matter most. To achieve this, we will discover, develop, and commercialize transformative medicines – either with in-house capabilities or together with partners – and evolve Idorsia into a leading biopharmaceutical company, with a strong scientific core. Headquartered near Basel, Switzerland – a European biotech hub – Idorsia has a highly experienced team of dedicated professionals, covering all disciplines from bench to bedside; QUVIVIQ™ (daridorexant), a different kind of insomnia treatment with the potential to revolutionize this mounting public health concern; strong partners to maximize the value of our portfolio; a promising in-house development pipeline; and a specialized drug discovery engine focused on small-molecule drugs that can change the treatment paradigm for many patients. Idorsia is listed on the SIX Swiss Exchange (ticker symbol: IDIA). For further information, please contact:Investor & Media RelationsIdorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil+41 58 844 10 – – The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Attachment Press Release PDF
Yahoo
4 days ago
- Yahoo
Denver celebrates five years of Healthy Food for Denver's Kids initiative
DENVER (KDVR) — Denver is celebrating the halfway point of its 10-year-long Healthy Food for Denver's Kids initiative. The initiative has invested more than $85 million into over 100 local organizations that work to increase access to nutritious food and food-based education for youth and their families, the city said Thursday. Lawsuit against Purina plant's 'rancid' odor dismissed 'Every child and family deserve the chance to access affordable, nutritious food,' Denver Mayor Mike Johnston said in a statement. The Healthy Food for Denver's Kids initiative was put in place following a voter-approved ballot initiative in 2018, with funding currently in place through 2029. 'Healthy Food for Denver's Kids has transformed how we support families in our city: making healthy meals more available, empowering communities, and ensuring equity regardless of where families live or their budgets,' Johnston said. This milestone is a powerful reminder of what we can achieve when we invest in our kids and their futures.' Since 2019, the city said Healthy Food for Denver's Kids has: Reached more than 149,000 families across Denver Served more than 40 million healthy and 'culturally relevant' meals and snacks Supported programming delivered in 33 languages Funded efforts in schools, nonprofits and public agencies focused on nutrition, food justice and youth empowerment The city is marking the milestone with a public celebration on Saturday at the Denver Zoo at the Zoo Gardens Plaza from 10 a.m. to 2 p.m. Zoo admission is required. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
